Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629852 | 0.90 | MEN1 (0.46) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13629853 | 0.90 | MEN1 (0.46) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13629863 | 0.86 | MEN1 (0.46) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13629864 | 0.85 | MEN1 (0.46) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13630619 | 0.80 | MEN1 (0.45) | MEN1KMT2ANPC1PSMD14GAA | |
| SCHEMBL13630611 | 0.80 | MEN1 (0.47) | MEN1KMT2ANPC1PSMD14GAA | |
| SCHEMBL13616364 | 0.79 | MEN1 (0.43) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13616363 | 0.79 | MEN1 (0.43) | MEN1KMT2ANPC1PSMD14AMY1A | |
| SCHEMBL13630616 | 0.79 | NPC1 (0.45) | MEN1KMT2ANPC1PSMD14GFER | |
| SCHEMBL13747638 | 0.76 | MEN1 (0.41) | MEN1KMT2ANPC1PSMD14AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | MEN1 4697/4885KMT2A 1752/4885NPC1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.